SCHEMBL2926095

SCHEMBL2926095

CSc1cnc2c(c1)cc([Si](C)(C)C)n2S(=O)(=O)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.40
ALDH1A1 P00352 3/20 0.38
TSHR P16473 2/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
MAPT P10636 4/20 0.36
LMNA P02545 1/20 0.36
HTR6 P50406 4/20 0.35
CXCL8 P10145 1/20 0.35
NOD1 Q9Y239 1/20 0.35
TP53 P04637 2/20 0.34
CYP2C19 P33261 1/20 0.34
GAA P10253 1/20 0.34
RECQL P46063 1/20 0.33
SRC P12931 1/20 0.33
BRD4 O60885 2/20 0.33
HTR2B P41595 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1359027 0.84 ENPP3 (0.45) HPGDALDH1A1SMN1; SMN2MAPTLMNA
SCHEMBL2926540 0.81 HPGD (0.41) HPGDALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL2928089 0.79 ALDH1A1 (0.51) HPGDALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL2928170 0.79 HTR6 (0.43) HPGDALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL2928077 0.78 ALDH1A1 (0.36) HPGDALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL2928711 0.78 ALDH1A1 (0.38) HPGDALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL2924501 0.78 MAPT (0.42) HPGDALDH1A1TSHRRAB9ANPC1
SCHEMBL2928668 0.75 CYP2C19 (0.58) HPGDALDH1A1TSHRLMNAHTR6
SCHEMBL1960830 0.72 HDAC3 (0.41) HPGDALDH1A1SMN1; SMN2MAPTLMNA
SCHEMBL10551779 0.70 HTR6 (0.40) ALDH1A1MAPTLMNAHTR6CXCL8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1086950-B1 HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-09-29 EP disclosed
US-7612070-B2 Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-11-03 US disclosed
US-20050137202-A1 Indole derivative having heterocycle and mono- or diazaindole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-06-23 US disclosed
US-6875770-B2 Indole derivative having heterocycle and mono- or diazaindole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-04-05 US disclosed
US-20040067964-A1 Indole derivative having heterocycle and mono- or diazaindole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-04-08 US disclosed
US-6673797-B1 CYCLOOXYGENASE-2 INHIBITORS; TREATING INFLAMMATORY DISEASE INDUCED BY CYCLOOXYGENASE-2 CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-01-06 US disclosed
EP-1086950-A1 HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137202-A1 Indole derivative having heterocycle and mono- or diazaindole derivative PTGS2, IDO2, IDO1 HPGD 31/4885ALDH1A1 228/4885TSHR 3338/4885
US-20040067964-A1 Indole derivative having heterocycle and mono- or diazaindole derivative IDO1, PTGS1, IDO2 HPGD 31/4885ALDH1A1 176/4885TSHR 3829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.